BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 22437309)

  • 1. Role of integrins in regulating proteases to mediate extracellular matrix remodeling.
    Yue J; Zhang K; Chen J
    Cancer Microenviron; 2012 Dec; 5(3):275-83. PubMed ID: 22437309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase plasminogen activator system as a potential target for cancer therapy.
    Mekkawy AH; Morris DL; Pourgholami MH
    Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.
    Skrzydlewska E; Sulkowska M; Koda M; Sulkowski S
    World J Gastroenterol; 2005 Mar; 11(9):1251-66. PubMed ID: 15761961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple pathways of cell invasion are regulated by multiple families of serine proteases.
    Del Rosso M; Fibbi G; Pucci M; D'Alessio S; Del Rosso A; Magnelli L; Chiarugi V
    Clin Exp Metastasis; 2002; 19(3):193-207. PubMed ID: 12067200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
    Masson V
    Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The urokinase-type plasminogen activator system and its role in tumor progression].
    Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
    Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
    Sidenius N; Blasi F
    Cancer Metastasis Rev; 2003; 22(2-3):205-22. PubMed ID: 12784997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
    Niedbala MJ; Sartorelli AC
    Cancer Commun; 1990; 2(5):189-99. PubMed ID: 2142433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of urokinase-type plasminogen activator system in cancer: an overview.
    Mekkawy AH; Pourgholami MH; Morris DL
    Med Res Rev; 2014 Sep; 34(5):918-56. PubMed ID: 24549574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enterolactone Suppresses Proliferation, Migration and Metastasis of MDA-MB-231 Breast Cancer Cells Through Inhibition of uPA Induced Plasmin Activation and MMPs-Mediated ECM Remodeling.
    Mali AV; Joshi AA; Hegde MV; Kadam ShS
    Asian Pac J Cancer Prev; 2017 Apr; 18(4):905-915. PubMed ID: 28545187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of proteases as anticancer drugs.
    Jedinak A; Maliar T
    Neoplasma; 2005; 52(3):185-92. PubMed ID: 15875078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
    Tang L; Han X
    Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion.
    Bellail AC; Hunter SB; Brat DJ; Tan C; Van Meir EG
    Int J Biochem Cell Biol; 2004 Jun; 36(6):1046-69. PubMed ID: 15094120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
    Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
    J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase induces receptor mediated brain tumor cell migration and invasion.
    MacDonald TJ; DeClerck YA; Laug WE
    J Neurooncol; 1998 Dec; 40(3):215-26. PubMed ID: 10066093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
    Reuning U; Magdolen V; Hapke S; Schmitt M
    Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
    Shirasuna K; Saka M; Hayashido Y; Yoshioka H; Sugiura T; Matsuya T
    Cancer Res; 1993 Jan; 53(1):147-52. PubMed ID: 8380125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
    Santibanez JF; Krstic J
    Curr Protein Pept Sci; 2018; 19(12):1155-1163. PubMed ID: 29086689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling.
    Madsen CD; Sidenius N
    Eur J Cell Biol; 2008 Sep; 87(8-9):617-29. PubMed ID: 18353489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases and their role in oncogenesis: a review.
    Pytliak M; Vargová V; Mechírová V
    Onkologie; 2012; 35(1-2):49-53. PubMed ID: 22310347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.